The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1647
April 4, 2022
View Complete Issue         Table of Contents 2019 
Drugs for GERD and Peptic Ulcer Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Drugs for GERD and Peptic Ulcer Disease
April 4, 2022 (Issue: 1647)
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Drugs for GERD and Peptic Ulcer Disease
Article code: 1647a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.